Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 18/20 | 0.61 |
| ▸ | CDK9 | P50750 | 2/20 | 0.61 |
| ▸ | CDK1 | P06493 | 3/20 | 0.56 |
| ▸ | CCNE1 | P24864 | 15/20 | 0.52 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.52 |
| ▸ | FLT3 | P36888 | 1/20 | 0.50 |
| ▸ | CCNE2 | O96020 | 14/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 14/20 | 0.48 |
| ▸ | CCNA1 | P78396 | 14/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23547403 | 0.91 | CDK2 (0.55) | CDK2CDK9CDK1CCNE1CCNB1 | |
| SCHEMBL30911090 | 0.91 | CDK2 (0.55) | CDK2CDK9CDK1CCNE1CCNB1 | |
| SCHEMBL3306974 | 0.85 | CDK2 (0.60) | CDK2CDK9CDK1CCNE1CCNB1 | |
| SCHEMBL13057362 | 0.85 | CDK2 (0.60) | CDK2CDK9CDK1CCNE1CCNB1 | |
| SCHEMBL10137840 | 0.85 | CDK2 (0.60) | CDK2CDK9CDK1CCNE1CCNB1 | |
| SCHEMBL31064238 | 0.84 | CDK2 (0.49) | CDK2CDK9CDK1CCNE1CCNB1 | |
| SCHEMBL13057363 | 0.83 | CDK2 (0.57) | CDK2CDK9CDK1CCNE1CCNB1 | |
| SCHEMBL3130740 | 0.82 | CDK2 (0.56) | CDK2CDK9CDK1CCNE1CCNB1 | |
| SCHEMBL23547401 | 0.81 | ALDH1A1 (0.51) | CDK2CDK9CDK1CCNA2 | |
| SCHEMBL26027585 | 0.81 | CDK2 (0.47) | CDK2CDK1CCNE1CCNB1CCNE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016820-A1 | Lipid Disulfide Prodrugs and Uses Related Thereto | UNIV EMORY (US) | 2024-01-18 | — | — | US | disclosed |
| US-11801255-B2 | Lipid disulfide prodrugs and uses related thereto | EMORY UNIVERSITY (US) | 2023-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240016820-A1 | Lipid Disulfide Prodrugs and Uses Related Thereto | SMPD1, SGMS1, SGMS2 | CDK2 2563/4885CDK9 3309/4885CDK1 2513/4885 |
| US-11801255-B2 | Lipid disulfide prodrugs and uses related thereto | SMPD1, SGMS1, GSTO1 | CDK2 2495/4885CDK9 3256/4885CDK1 2497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.